ASND
Price
$228.07
Change
-$1.98 (-0.86%)
Updated
Sep 29 closing price
Capitalization
15.13B
42 days until earnings call
Intraday BUY SELL Signals
BCYC
Price
$3.65
Change
-$0.06 (-1.62%)
Updated
Sep 29 closing price
Capitalization
259.67M
30 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ASND vs BCYC

ASND vs BCYC Comparison Chart in %
View a ticker or compare two or three
VS
ASND vs. BCYC commentary
Sep 30, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASND is a StrongBuy and BCYC is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ASND vs BCYC: Fundamental Ratings
ASND
BCYC
OUTLOOK RATING
1..100
6861
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
9
Undervalued
PROFIT vs RISK RATING
1..100
58100
SMR RATING
1..100
1297
PRICE GROWTH RATING
1..100
5879
P/E GROWTH RATING
1..100
84100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (9) in the null industry is significantly better than the same rating for ASND (76) in the Biotechnology industry. This means that BCYC’s stock grew significantly faster than ASND’s over the last 12 months.

ASND's Profit vs Risk Rating (58) in the Biotechnology industry is somewhat better than the same rating for BCYC (100) in the null industry. This means that ASND’s stock grew somewhat faster than BCYC’s over the last 12 months.

ASND's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for BCYC (97) in the null industry. This means that ASND’s stock grew significantly faster than BCYC’s over the last 12 months.

ASND's Price Growth Rating (58) in the Biotechnology industry is in the same range as BCYC (79) in the null industry. This means that ASND’s stock grew similarly to BCYC’s over the last 12 months.

ASND's P/E Growth Rating (84) in the Biotechnology industry is in the same range as BCYC (100) in the null industry. This means that ASND’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASNDBCYC
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 16 days ago
70%
Bullish Trend 16 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
73%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
COMPARISON
Comparison
Sep 30, 2026
Stock price -- (ASND: $228.07 vs. BCYC: $3.71)
Brand notoriety: ASND and BCYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASND: 95% vs. BCYC: 122%
Market capitalization -- ASND: $15.13B vs. BCYC: $259.67M
ASND [@Biotechnology] is valued at $15.13B. BCYC’s [@Biotechnology] market capitalization is $259.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASND’s FA Score shows that 1 FA rating(s) are green while BCYC’s FA Score has 1 green FA rating(s).

  • ASND’s FA Score: 1 green, 4 red.
  • BCYC’s FA Score: 1 green, 4 red.
According to our system of comparison, ASND is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASND’s TA Score shows that 5 TA indicator(s) are bullish while BCYC’s TA Score has 4 bullish TA indicator(s).

  • ASND’s TA Score: 5 bullish, 5 bearish.
  • BCYC’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ASND is a better buy in the short-term than BCYC.

Price Growth

ASND (@Biotechnology) experienced а -4.00% price change this week, while BCYC (@Biotechnology) price change was +2.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.40%. For the same industry, the average monthly price growth was -11.74%, and the average quarterly price growth was +0.75%.

Reported Earning Dates

ASND is expected to report earnings on Nov 11, 2026.

BCYC is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-6.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ASND
Daily Signal:
Gain/Loss:
BCYC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DLFE32.49-0.06
-0.18%
FT Vest U.S. Equity Dual Directional Buffer ETF - February
QVMS32.30-0.17
-0.52%
Invesco S&P SmallCap 600 QVM Multi-factor ETF (QVMS)
SPHQ84.40-0.52
-0.61%
Invesco S&P 500 Quality ETF (SPHQ)
ITDJ33.14-0.28
-0.84%
iShares LifePath Target Date 2070 ETF
MSTU41.85-0.99
-2.31%
T-Rex 2X Long MSTR Daily Target ETF (MSTU)

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with DNLI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+0.68%
DNLI - BCYC
49%
Loosely correlated
+2.89%
PCVX - BCYC
48%
Loosely correlated
+3.66%
NGNE - BCYC
46%
Loosely correlated
+0.60%
SANA - BCYC
46%
Loosely correlated
-0.51%
KURA - BCYC
45%
Loosely correlated
-1.39%
More